Hemoglobinopathy

Catalyst Solutions Welcomes Dr. Vipul Mankad to its Advisory Board

Retrieved on: 
Wednesday, April 17, 2024
Education, Acos, Catalysis, Outsourcing, Hospital, Book, Integration, Health, Population health, Advisory board, Business process, As a service, BPO, Hemoglobinopathy, Physician, Health policy, Medicare, Data management, Multimedia, United States Senate, Nursing

GREENWOOD VILLAGE, Colo., April 17, 2024 /PRNewswire/ -- Catalyst Solutions , a leader in healthcare Business Process Outsourcing  as a Service (BPaaS), Business Process Outsourcing (BPO), technology, clinical, and consulting services, is pleased to welcome Dr. Vipul Mankad to our advisory board.

Key Points: 
  • GREENWOOD VILLAGE, Colo., April 17, 2024 /PRNewswire/ -- Catalyst Solutions , a leader in healthcare Business Process Outsourcing  as a Service (BPaaS), Business Process Outsourcing (BPO), technology, clinical, and consulting services, is pleased to welcome Dr. Vipul Mankad to our advisory board.
  • During his academic career, Dr. Mankad directed a Physician Group Practice of 480 physicians with an annual revenue of $ 110 million and founded the Kentucky Children's Hospital.
  • In addition to being on the Catalyst advisory board, Dr. Mankad presides over his non-profit family foundation to support health and education worldwide.
  • Sas Mukherjee, Catalyst Solutions' President said, "We are honored by the confidence Dr. Mankad has demonstrated by joining our Advisory Board.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Retrieved on: 
Tuesday, January 2, 2024
SCD, Medical Subject Headings, Marketing, Febrile neutropenia, European Commission, Sickle cell disease, INN, Limited, Hematology, Physician, ATC, EMA, B cell, International, ATMP, HLA, Vomiting, Headache, Thalassemia, Nausea, Tissue, Disease, Civil service commission, HSC, CD34, Cas9, Haematopoiesis, Vertex Pharmaceuticals, Public, Gene, Transplant, Medication package insert, Volatile organic compound, Committee, Patient, Liver disease, TDT, HBF, Mouth ulcer, Cell, Anatomy, Medicine, Hemoglobinopathy, BCL11A, Health, CHMP

Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Key Points: 


Human medicines European public assessment report (EPAR): Casgevy, Exagamglogene autotemcel, Status: Opinion

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

Retrieved on: 
Sunday, December 10, 2023
Momentum, Agios Pharmaceuticals, Erythropoiesis, Sickle cell disease, Agios, Exposition, Hemoglobinopathy, Arm, BID, Trial of the century, University of Texas System, Sickle cell trait, Pain, Female, Headache, Disease, Fatigue, Dysmenorrhea, Nausea, Anemia, Society, Influenza-like illness, Therapy, ASH, Death, Marker, Back pain, University, AGIO, Medicine, Arthralgia

CAMBRIDGE, Mass., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today presented detailed results from the Phase 2 portion of the global RISE UP study of mitapivat in sickle cell disease in an oral presentation (abstract #271) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being hosted Dec. 9-12, 2023, in San Diego.

Key Points: 
  • The safety profile for mitapivat observed in the study was generally consistent with previously reported data in other studies of sickle cell disease and other hemolytic anemias.
  • Improvements were observed in annualized rates of sickle cell pain crises, and markers of hemolysis and erythropoiesis for both mitapivat treatment arms compared to placebo.
  • “Currently there are no approved oral therapies that address both sickle cell pain crises and chronic anemia, two of the hallmark symptoms of the disease.
  • Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients With Sickle Cell Disease: RISE UP Phase 2 Results
    Oral Abstract Session: 114.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Cancer, Doctor of Philosophy, Khalifa University, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Tuesday, November 21, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Retrieved on: 
Monday, November 20, 2023
Hospital, Genetic counseling, Partnership, Medicine, Physician, International Center, Prognosis, Excellency, Trustee, Diabetes, Emirate, Health, Doctor of Philosophy, Khalifa University, Cancer, Mass, Genomics, Knowledge, Genetics, Public, Mass General Brigham, DSM-IV codes, Harvard University, FACMG, Patient, Diagnosis, Risk management, Harvard Medical School, MSHA, Hemoglobinopathy, Pharmaceutical industry

To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.

Key Points: 
  • To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling.
  • This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology.
  • This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide.
  • Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham.